Sai Parenterals Limited, a Hyderabad-based pharmaceutical manufacturer, has raised Rs 50 crore in equity funding from a consortium of institutional investors. The funding round was led by Samarsh Capital, Vyom Partners, and funds associated with Blue Lotus Capital.
The company said the capital will be used to fuel its global expansion strategy, including acquisitions in regulated markets, enhancement of its manufacturing footprint, and diversification of its product portfolio.
“We are working diligently to build a world-class pharmaceutical company that adheres to the highest global standards,” said Anil Karusala, Managing Director of Sai Parenterals. “This equity infusion will allow us to acquire high-potential international assets and intellectual property, expand our geographical presence, and enhance our capabilities.”
Founded in 2001, Sai Parenterals operates across the pharmaceutical value chain—from research and development to manufacturing and export. It serves two primary business verticals: branded export formulations and contract development and manufacturing (CDMO) services. The company’s offerings span sterile injectables, oral solids and liquids, and topical preparations.
Sai Parenterals currently operates five facilities in India, with select units approved by international regulators including TGA (Australia), WHO-GMP, SAPRA, and GCC authorities. It has a growing presence in South Asia, Africa, the Middle East, and other emerging markets.
Investors cited the company’s execution capabilities and international growth potential as key factors behind their participation in the round.
“Our investment reflects confidence in Sai Parenterals’ fundamentals and its potential to emerge as a global leader,” said Sandeep Shenoy, Managing Partner at Samarsh Capital.
This is the second investment by Blue Lotus Capital in the company. “By partnering with a formidable player in sterile injectables, we aim to accelerate affordable, high-quality healthcare solutions for global markets,” said Harikrishnan S, Managing Partner at Blue Lotus.
The funding comes at a time when Indian pharmaceutical firms are expanding their global reach, particularly in sterile injectables and CDMO services, amid rising demand for cost-effective manufacturing and complex formulations.
Sai Parenterals said it will continue to pursue inorganic growth opportunities while building a science-led, capital-efficient platform serving both regulated and emerging markets.
Edited by Megha Reddy
